FDA Broadens Nicotine Therapy Indication Review With Steering Committee Docket
Executive Summary
FDA seeks broader guidance than comments and information submitted at a January public hearing on standards testing and evaluations that could expand the variety of products approved as NRTs The docket is open to "recommend specific topics for direct, collective engagement and consideration by the" steering committee.
You may also be interested in...
Top US FDA Drug Policy Leader Leaving For White House Detail
Grail Sipes, CDER deputy center director for regulatory policy, will move to the Executive Office of the President next month.